Thomas P. Leist, MD, PhD

Thomas P. Leist, MD, PhD

Contact Dr. Leist

900 Walnut Street
Suite 200
Philadelphia, PA 19107

(215) 955-6871
(215) 503-2990 fax

Most Recent Peer-reviewed Publications

  1. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis
  2. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
  3. Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse
  4. Expression of GM-CSF in T cells is increased in multiple sclerosis and suppressed by IFN-β therapy
  5. Therapy optimization in multiple sclerosis: A prospective observational study of therapy compliance and outcomes
  6. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): A phase 3 randomised trial
  7. Relevance of MOA in MS treatment efficacy
  8. Case scenario #2
  9. Case scenario #1
  10. Novel Therapeutics in Multiple Sclerosis Management: Clinical Applications
  11. Multitasking in multiple sclerosis: Can it inform vocational functioning?
  12. Cladribine: Mode of action and implications for treatment of multiple sclerosis
  13. Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics
  14. Human optic nerve DTI with EPI geometric distortion correction
  15. Thickness of retinal nerve fiber layer correlates with disease duration in parallel with corticospinal tract dysfunction in untreated multiple sclerosis
  16. Toward a practical protocol for human optic nerve DTI with EPI geometric distortion correction
  17. When metals compete: A case of copper-deficiency myeloneuropathy and anemia
  18. Phase Labeling Using Sensitivity encoding (PLUS): Data acquisition and image reconstruction for geometric distortion correction in EPI
  19. Geometric distortion correction in EPI by phase labeling using sensitivity encoding (PLUS)
  20. Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up